CellCentric raises $26 million to take first-in-class p300/CBP inhibitor into the clinic
May 15th 2018 CellCentric has raised $26 million in private financing to fund clinical testing…
read moreEpigenetics is the study of the control mechanisms that sit on top of genes and guide the function and fate of individual cells. The field is expected to radically change traditional approaches to many healthcare areas, including cancer therapeutics and tissue regeneration.
Status current
Associated Fund UK Innovation & Science Seed Fund
Sector Medical / Biotechnology
Website www.cellcentric.com/
“Interactions with Midven have always been open and straightforward. Investments have always been clearly structured and compatible with others, including high net worths, Institutional and corporate investors.”
Will West, Cellcentric
May 15th 2018 CellCentric has raised $26 million in private financing to fund clinical testing…
read moreProduction of CCS1477 in capsule form is now complete, ahead of forthcoming first-in-human clinical trials…
read moreCellCentric is developing first in class drug compounds against a key regulator of cancer. P300/CBP…
read moreNew investment coupled with a major award from the UK’s innovation agency, the Technology Strategy…
read more